tDCS - Further information on treating depression
Further information update on tDCS treatment at Altea Medical Centre.
US Medical studies show that In a randomised, double-blind, controlled trial, Brunoni et al found that the efficacy of transcranial direct current stimulation (tDCS) was comparable to that of sertraline (50 mg/day) in the treatment of major depression and that the combination of tDCS with sertraline was superior to sertraline alone.
There was a significant difference in depression rating scale score between, on one hand, the combined treatment group and, on the other, the sertraline-only (mean difference, 8.5 points), tDCS only (5.9 points), and placebo groups (11.5 points).
In 2019, the FDA approved a cranial electrotherapy stimulator (CES) for treatment of anxiety, depression, and insomnia. The prescription device delivers micro pulses of electrical current across the brain, which in clinical trials led to a reduction in anxiety levels, insomnia, and depressed mood.
AMC patients now receiving tDCS report an improvement in their wellbeing, sleep pattern and general ability to relax more easily.
For more information, please contact the clinic to discuss a free information sheet and or appointment with the Doctor running the procedure.
Telephone: +34 965 845 711